Compromiso de la médula ósea en linfomas agresivos : un concepto intuitivo.

Andrés Mauricio Acevedo; Martha Liliana Romero

doi:10.51643/22562915.346

Bone marrow involvement in aggressive lymphomas : an intuitive concept.

Compromiso de la médula ósea en linfomas agresivos : un concepto intuitivo.

Published 2013-10-01

Open | Download

PDF (Spanish) FLIP

Issue

Vol. 2 No. 3 (2013): Octubre

Section

Editorial

How to Cite

Bone marrow involvement in aggressive lymphomas : an intuitive concept.

Rev. colomb. hematol. oncol. [Internet]. 2013 Oct. 1 [cited 2024 Dec. 22];2(3):12-3. Disponible en: https://doi.org/10.51643/22562915.346

DOI

https://doi.org/10.51643/22562915.346

Dimensions

PlumX

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Andrés Mauricio Acevedo

Grupo Colombiano para la Investigación Clínica y Molecular del Cáncer (ONCOLGroup)

Martha Liliana Romero

Fundación Santa Fe de Bogotá

Show authors biography

Andrés Mauricio Acevedo,

Grupo Colombiano para la Investigación Clínica y Molecular del Cáncer (ONCOLGroup).

Martha Liliana Romero,

Departamento Laboratorio Clínico y Anatomía Patológica, Sección Hematopatología, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Article visits 89 | PDF visits 147

Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120(24):4795-801.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117-26.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503- 11.
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24(3):561-76.
Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The International NonHodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-94.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-7.
Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110(4):1278-82.